| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$136 |
NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
|
23 Jul 2025 8:30AM |
$0.350 |
$0.555 |
risen by
58.57%
|
|
NYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Nyrada Inc advances Xolatryp Phase IIa clinical trial in cardioprotection.
- The trial focuses on reducing cardiac damage during procedures that can cause myocardial injury.
- Xolatryp is a novel, first-in-class therapeutic candidate developed by Nyrada Inc.
- Previous preclinical and Phase I studies have been successfully completed.
- The company has secured regulatory approvals to commence the Phase IIa trial.
- Patient recruitment for the trial has begun.
- Xolatryp addresses an unmet need in cardiovascular medicine, specifically for cardioprotection.
- The trial will assess safety, pharmacokinetics, and preliminary efficacy endpoints.
- Nyrada Inc aims to reduce the global burden of cardiovascular disease through novel treatments.
- Xolatryp may represent a breakthrough in protecting heart tissue from ischemic damage.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$8,505 |
Growing Fuel and Convenience Earnings
|
23 Jul 2025 8:30AM |
$26.890 |
$35.690 |
risen by
32.73%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- Ampol Limited (ASX:ALD) reported a Group Replacement Cost Operating Profit (RCOP) EBITDA of ~$640 million for the first half of the 2025 financial year.
- Convenience Retail segment showed growth in EBIT, driven by a favorable mix of premium fuels.
- New Zealand segment achieved modestly higher EBIT due to diversified market channels.
- Fuels & Infrastructure (F&I) Australia EBIT was similar to the previous year, with supply chain impacts mitigated by better margins in middle distillates.
- F&I International operations remained at breakeven, focusing on supply within the Ampol system.
- Lytton refinery's EBIT was around breakeven, supported by improved Lytton Refiner Margin.
- Ampol's interest expense and effective tax rate are expected to remain favorable.
- Further audited financial results will be released on 18 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$8,505 |
Growing Fuel and Convenience Earnings
|
23 Jul 2025 8:30AM |
$26.890 |
$35.690 |
risen by
32.73%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- Ampol Limited reported a Group RCOP EBITDA of ~$640 million and RCOP EBIT of ~$400 million for the first half of 2025.
- Convenience Retail continued its trend of growing earnings, driven by a favorable mix of premium fuels.
- New Zealand segment achieved modest EBIT growth, benefiting from diversified market channels.
- Fuels & Infrastructure (F&I) Australia maintained EBIT levels comparable to the previous year.
- Lytton refinery's EBIT was around breakeven in the first half of 2025, supported by an improved Lytton Refiner Margin.
- The interest expense for 1H 2025 is expected to be in line with the prior period.
- Convenience Retail’s U-GO expanded to 34 sites in Australia.
- Overall Group sales volume decreased by 6.1% year-on-year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$467 |
June 2025 Quarterly Activity Report and Appendix 4C
|
23 Jul 2025 8:28AM |
$1.140 |
$2.470 |
risen by
116.67%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Report covers the quarter ending June 2025 for Race Oncology Ltd.
- Highlights significant clinical and preclinical progress, especially with bisantrene.
- Details updates on ongoing and planned clinical trials.
- Mentions collaborations with international research institutions.
- Provides regulatory and intellectual property developments.
- Appendix 4C includes a summary of cash receipts, expenditures, and end-of-quarter cash balance.
- Company maintains a strong focus on advancing its lead drug candidate.
- Operational activities are aligned with research and development goals.
- Financial position detailed in Appendix 4C supports ongoing business activities and research programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scentre Group (SCG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$19,012 |
DXS:DWSF Westfield Chermside investment and DXS transactions
|
23 Jul 2025 8:27AM |
$3.730 |
$3.640 |
fallen by
2.41%
|
|
| Dexus (DXS) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$6,521 |
DWSF Westfield Chermside investment and DXS transactions
|
23 Jul 2025 8:27AM |
$7.050 |
$6.080 |
fallen by
13.76%
|
|
| Westpac Banking Corporation (WBC) ORDINARY FULLY PAID |
Financials |
$124,465 |
Update - Notification of buy-back - WBC
|
23 Jul 2025 8:27AM |
$32.650 |
$36.390 |
risen by
11.45%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$12 |
Completion of Recruitment in TRIPP-FFX Clinical Trial
|
23 Jul 2025 8:27AM |
$1.185 |
$0.390 |
fallen by
67.09%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited has completed recruitment for the TRIPP-FFX clinical trial.
- The TRIPP-FFX trial investigates the OncoSil™ device in combination with FOLFIRINOX for locally advanced pancreatic cancer.
- A total of 71 patients have been enrolled in the study.
- Clinical sites for the trial are located internationally.
- Completion of recruitment marks a major milestone in the company’s clinical program.
- The next steps involve data analysis and preparation for regulatory and commercial processes.
- The OncoSil™ device is designed to deliver targeted radiation directly to pancreatic tumors.
- The company acknowledges the contribution of patients, investigators, and clinical teams.
- Further updates will be provided as trial data becomes available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sovereign Metals Limited (SVM) ORDINARY FULLY PAID |
Materials |
$420 |
DFS Progressing Well with Completion of Geotechnical Program
|
23 Jul 2025 8:26AM |
$0.760 |
$0.640 |
fallen by
15.79%
|
|
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,923 |
Q4, FY25 Webcast Presentation
|
23 Jul 2025 8:25AM |
$2.860 |
$5.210 |
risen by
82.17%
|
|
| Galileo Mining Ltd (GAL) ORDINARY FULLY PAID |
Materials |
$24 |
Norseman PGE Project Drill Program in Progress
|
23 Jul 2025 8:24AM |
$0.165 |
$0.120 |
fallen by
27.27%
|
|
GAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Galileo Mining Ltd is advancing drilling activities at the Norseman PGE Project.
- The program targets nickel, copper, and cobalt mineralization with a focus on the Callisto discovery.
- Reverse circulation (RC) and diamond drilling methods are being utilized across multiple prospects.
- Early drill results are positive, with further assay results pending.
- Geological and geophysical data are being used to guide the exploration strategy.
- The company is systematically exploring for PGE-nickel-copper sulphide mineralization.
- Future exploration plans are underway to expand on current discoveries.
- The drill program is part of a broader strategy for resource development at Norseman.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,662 |
Net Tangible Asset Backing
|
23 Jul 2025 8:22AM |
$3.000 |
$4.200 |
risen by
40%
|
|
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,923 |
June 2025 Quarterly Results
|
23 Jul 2025 8:22AM |
$2.860 |
$5.210 |
risen by
82.17%
|
|
WGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record gold production of 88,022 ounces achieved in Q4 FY25.
- All-In Sustaining Cost (AISC) for Q4 FY25 was $237 million, equating to $2,688 per ounce.
- Westgold Resources Limited announced a maiden Mineral Resource Estimate of 2.3 million ounces for the Fletcher Zone at Beta Hunt.
- Total cash, bullion, and investments increased to $364 million by the end of Q4 FY25.
- Westgold remains 100% unhedged and achieved an average gold price of $5,174 per ounce in Q4 FY25.
- Capital expenditure for Q4 FY25 totaled $39 million, primarily invested in growth projects and equipment.
- Westgold's net mine cashflow for Q4 FY25 was $171 million.
- Mining rates improved quarter on quarter in key operations including Bluebird-South Junction.
- The company plans to release FY26 guidance in August and a 3-year outlook in September FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,923 |
June 2025 Quarterly Results
|
23 Jul 2025 8:22AM |
$2.860 |
$5.210 |
risen by
82.17%
|
|
WGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record gold production of 88,022 ounces in Q4 FY25.
- Achieved gold price of $5,174 per ounce.
- Revenue generated was $370 million for the quarter.
- Strong cash position of $364 million at the end of Q4 FY25.
- Investments in growth projects and exploration totaled $39 million and $9 million respectively.
- Safety performance improved, with a reduced Total Recordable Injury Frequency Rate.
- Maiden Mineral Resource Estimate of 2.3Moz announced for the Fletcher Zone at Beta Hunt.
- Westgold remains unhedged, fully exposed to the spot gold price.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mitchell Services Limited (MSV) ORDINARY FULLY PAID |
Materials |
$102 |
Quarterly Investor Update
|
23 Jul 2025 8:18AM |
$0.300 |
$0.480 |
risen by
60%
|
|
MSV - Price-sensitive ASX Announcement
Full Release
Key Points
- MSV reported strong revenue and EBITDA for the March 2024 quarter.
- The company has secured several new contracts and contract extensions, underpinning future revenue.
- Mining sector demand for drilling services remains high, supporting elevated fleet utilisation rates.
- Workforce numbers have increased to meet operational requirements.
- Strategic investment in fleet upgrades and technology continues to drive efficiency and competitiveness.
- Safety performance remains a central focus, with ongoing improvements and initiatives.
- Management commentary addresses current market conditions and operational challenges.
- The report includes summaries of financial performance and outlook statements for upcoming quarters.
- Investor relations contacts and company information are provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubalus Resources Limited (BUS) ORDINARY FULLY PAID |
Materials |
$6 |
Compelling Fosterville-Style Targets at Crosbie North
|
23 Jul 2025 8:18AM |
$0.091 |
$0.093 |
risen by
2.20%
|
|
BUS - Price-sensitive ASX Announcement
Full Release
Key Points
- Bubalus Resources Limited has identified a high-priority Fosterville-style gold target at Crosbie North in Western Australia.
- The target zone is defined by significant arsenic and antimony anomalies, which are key pathfinder elements for gold mineralization.
- Geochemical and structural signatures at Crosbie North are considered analogous to those found at the Fosterville Gold Mine.
- The company plans to conduct further geophysical surveys and follow-up drilling to test the new targets.
- The Amadeus Project's geological setting is favorable for the discovery of high-grade gold mineralization.
- Future work will focus on refining targets and advancing exploration to unlock the project's potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$6 |
HITIQ Appoints Nathan Murphy as Brand Ambassador
|
23 Jul 2025 8:18AM |
$0.020 |
$0.008 |
fallen by
60%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$405 |
Update - Notification of buy-back - RG8
|
23 Jul 2025 8:18AM |
$2.030 |
$2.820 |
risen by
38.92%
|
|
| Orica Limited (ORI) ORDINARY FULLY PAID |
Materials |
$10,690 |
Update - Notification of buy-back - ORI
|
23 Jul 2025 8:18AM |
$21.270 |
$23.070 |
risen by
8.46%
|
|
| Plenti Group Limited (PLT) ORDINARY FULLY PAID |
Financials |
$149 |
1Q26 update - another record quarter
|
23 Jul 2025 8:17AM |
$0.930 |
$0.815 |
fallen by
12.37%
|
|
PLT - Price-sensitive ASX Announcement
Full Release
Key Points
- Loan originations reached $581 million in 1Q26, up 24% year-on-year.
- Total loan portfolio grew to $2.3 billion, marking continued portfolio expansion.
- Revenue for the quarter increased by 36% to $59 million.
- Automotive and renewable energy lending were the primary growth drivers.
- Credit quality remained robust with net losses and arrears below historical averages.
- Plenti reaffirmed its FY26 guidance for growth and profitability.
- Ongoing investment in technology, product innovation, and partnerships supported performance.
- Market share gains were achieved across target lending verticals.
- Funding position remains strong, supporting further growth ambitions.
- Focus on operational efficiency and cost discipline continues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Canterbury Resources Ltd (CBY) ORDINARY FULLY PAID |
Materials |
$15 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
23 Jul 2025 8:17AM |
$0.024 |
$0.054 |
risen by
125%
|
|
CBY - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Cash Flow Report for period ending 31 March 2023.
- Exploration activities continued across Bismarck, Briggs, Ekoato, and Wamum projects.
- Briggs copper project in Queensland saw resource drilling and technical reviews.
- Ekoato project in Papua New Guinea advanced with geological mapping and sampling.
- Ongoing engagement with potential partners to support project development.
- No mining production; activities remain focused on exploration.
- Cash outflows primarily for exploration and administration.
- Strong cash position at end of quarter with prudent cost management.
- Appendix 5B included summarizing financials for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lake Resources NL (LKE) ORDINARY FULLY PAID |
Materials |
$174 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
23 Jul 2025 8:17AM |
$0.038 |
$0.075 |
risen by
97.37%
|
|
LKE - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly activities report for December 2023 released by Lake Resources NL.
- Progress made on the Kachi Lithium Brine Project in Argentina, with a revised DFS and updated Mineral Resource Estimate delivered.
- Corporate restructure undertaken, including leadership changes and appointment of a new CEO.
- Cost reduction and operational streamlining measures implemented.
- Continued technical advancement in Direct Lithium Extraction pilot operations.
- Ongoing engagement with potential strategic partners and project financiers.
- Report provides Appendix 5B cash flow, noting prudent financial management and cash balance at quarter end.
- Continued focus on strengthening project delivery capabilities and advancing lithium production efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Breakthrough Minerals Limited (BTM) ORDINARY FULLY PAID |
Energy |
$47 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
23 Jul 2025 8:17AM |
$0.125 |
$0.240 |
risen by
92%
|
|
BTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers period ending 31 March 2023.
- Focus on exploration activities at Cooletha and Laverton projects in Western Australia.
- Completion of follow-up soil sampling at Cooletha project.
- Planning for maiden drill program at Cooletha project.
- Ongoing community engagement and heritage surveys.
- Quarterly cash outflows primarily from exploration and administrative expenses.
- Cash and cash equivalents at quarter end reported.
- Company remains committed to advancing exploration assets and prudent financial management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AIC Mines Limited (A1M) ORDINARY FULLY PAID |
Materials |
$495 |
Investor Presentation
|
23 Jul 2025 8:17AM |
$0.320 |
$0.620 |
risen by
93.75%
|
|
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$625 |
3Q Trading Update Macquarie Conference Presentation
|
23 Jul 2025 8:17AM |
$3.110 |
$2.900 |
fallen by
6.75%
|
|
FPR - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Revenue After Funding Costs (NRAF) increased year-on-year, driven by volume growth and operating efficiencies.
- Novated and Fleet segments saw strong customer demand and portfolio growth.
- Net interest margin remained steady, reflecting effective funding cost management.
- Credit performance continues to be robust with low arrears and minimal credit losses.
- Investment in digital origination platforms enhanced customer acquisition and process efficiency.
- Focused on operational discipline and cost management to protect margins.
- Maintained strong balance sheet and capital position, supporting future growth and shareholder returns.
- Confirmed full-year FY24 guidance, underpinned by diversified earnings and resilient business model.
- Continued focus on sustainability, customer experience, and digital innovation.
- Management is committed to delivering value for shareholders through disciplined execution and strategic growth initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
